Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 4 hours ago
- 1 min read
22/02/2026
MoonLake announced topline results from its Phase 2 study of sonelokimab in axial spondyloarthritis (Ref)
MoonLake Immunotherapeutics announced positive topline results from its Phase 2, S-OLARIS study evaluating sonelokimab (IL-17A and IL-17F inhibitor) in patients with radiographic and non-radiographic axial spondyloarthritis
The study demonstrated a clinically meaningful and statistically significant benefit:
81% of patients achieved an Assessment of Spondyloarthritis International Society 40 (ASAS40) response at Week 12
80% of patients achieved a clinically important improvement as per ASDAS-CRP score by Week 12
As a biomarker-controlled trial, S-OLARIS data showed that sonelokimab reduced the levels of key inflammatory mediators in axSpA, in peripheral blood and biopsy samples from patients
The safety profile of sonelokimab was similar to that observed in other trials and no new signals were detected
